Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discrepancy in ketamine IC50 values between these two studies might be explained by the concentration of agonist used (50 μM versus 1 mM glutamate), as higher agonist concentrations allow non-competitive antagonists, e.g. ketamine, to block more effectively due to a greater number of open channels”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lipton, 2006
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972 · cited 1×
“D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK293 and N1E-115 cell systems in a non-competitive manner.”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139 · cited 1×
“The NR2 family of NMDAR subunits contains a binding site for glutamate, the endogenous agonist, whereas the NR1 subunit binds glycin”
BackgroundVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658 · cited 1×
“kon Channel + MEM ↔ Channel–MEM (Blocked channel) (1)”
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Research works printed but not linked: 5
- Chen, H. -S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
- Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247–A238 (2005).
- Lipton, S. A., Rayudu, P. V., Choi, Y. -B., Sucher, N. J. & Chen, H. -S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73–82 (Elsevier, Amsterdam, 1998).
- Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
- Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
Cited by
Items 801–900 of 943
Kwong, J. M. K., & Pang, I. (2019) · Springer eBooks · doi:10.1007/978-981-13-2733-9_7 · Cited by 2
Cell and Tissue Destruction in Selected Disorders
Arnhold, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816388-7.00009-7 · Cited by 1
Computational support of structure-based targeted covalent inhibitor design
Abel, R., & Friesner, R. A. (2021) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2021.01.001 · Cited by 2
Lowe, J. A., III (2013) · Wiley eBooks · doi:10.1002/9781118354483.ch7 · Cited by 1
Agrawal, P., Giron, L. B., Singh, S. T., Haw, N. J., Goldman, A. R., Elkaeid, M., Macatangay, B. J. C., Palella, F. J., Alcaide, M. L., Moran, C. A., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae362 · Cited by 1
Sobów, T. (2014) · Aktualności Neurologiczne · doi:10.15557/an.2014.0006 · Cited by 1
Clinically Tolerated Strategies for NMDA Receptor Antagonism
Chen, H.-S. V., Zhang, D., & Lipton, S. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-055-3_8 · Cited by 1
“The cascade of steps leading to neuronal cell death include (1) NMDAR hyperactivation; (2) activation of the p38 mitogen activated kinase (MAPK)–myocyte-specific enhancer factor 2C (MEF2C) (transcription factor) pathway (MEF2C is subsequently cleaved by caspases to form an endogenous dominant-interfering form that con…”
BackgroundSelf-citationShift Shown in Influenza A Adamantane Resistance
Shea, K. M. (2006) · JAMA · doi:10.1001/jama.296.13.1585-a · Cited by 1
Detecting the effects of neuroprotection in living cells
Funk, R. H. W., Kniep, E.-M., & Roehlecke, C. (2007) · Eye · doi:10.1038/sj.eye.6702887 · Cited by 1
“Memantine is an N -methyl- D -aspartate-sensitive glutamate receptor antagonist, which has been suggested to have neuroprotective effects by reducing glutamate-induced excitotoxicity”
BackgroundReply to: Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection
Oh, C.-K., Piña-Crespo, J., Talantova, M. V., Carnevale, L. N., Stoneham, C. A., Lewinski, M. K., Guatelli, J., & Lipton, S. A. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01425-z · Cited by 1
Self-citationNomethiazoles: PK/PD Study of a Novel Class of Alzheimer’s Disease Therapeutics
Tavassoli, E. (2012) · Figshare
Excitotoxicity in Neurodegenerative Disease
Haeberlein, S. L. B., & Lipton, S. A. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00498-8
Self-citationKotermanski, S. E. (2008) · D-Scholarship@Pitt (University of Pittsburgh)
Lewis, J. (2011) · UKnowledge (University of Kentucky)
From Reactive Oxygen and Nitrogen Species to Therapy
McKercher, S. R., Nakamura, T., & Lipton, S. A. (2009) · Wiley eBooks · doi:10.1002/9780470015902.a0021989
Self-citationNakamura, T., & Lipton, S. A. (2011) · Wiley eBooks · doi:10.1002/9781118063903.ch2
Self-citationEffects of pharmaceutical modulation of protein aggregation on lifespan in Caenorhabditis elegans
Klang, I. M. (2015) · Figshare
Modulation of NMDA Receptor Activity During Physiological and Pathophysiological Events
Emnett, C. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7wm1bj6
“In contrast, memantine is largely used for treating cognitive decline during Alzheimer’s disease (Orgogozo et al., 2002; Lipton, 2006).”
MethodRojas-Martinez, J. C. (2009) · Texas ScholarWorks (Texas Digital Library)
Molecular mechanisms of transneuronal interactions
Magazanik, L. G., & Никольский, Е. Е. (2010) · Herald of the Russian Academy of Sciences · doi:10.1134/s1019331610030032
Anti-N-methyl-D-aspartate receptor encephalitis in China
Li, L., Wang, C., & Zhao, G. (2014) · Neuroimmunology and Neuroinflammation · doi:10.4103/2347-8659.135571
“Subsequently, low-dose NMDA was used to investigate the roles of glutamate and glutamate-receptor pathway in the central nervous system (CNS).[1]”
Terada, S., & Uchitomi, Y. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.11.007
Effect of memantine in aging : the impact of hippocampal dependent memory
Pinho, J. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Management of glaucoma with neuroprotective drug
Islam, M. N. (1970) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v9i4.6685
Litvinenko, I., Vorobev, S., Lobzin, V. Y., & Lupanov, I. A. (2014) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-014-0035-y
Tarantello, C. (2009) · UPT. Syiah Kuala University Library (Syiah Kuala University)
ENHANCING THE VIRTUES OF STUDENTS
Enck, G. (2013)
Cui, W., Choi, T. C., Mak, S., Yu, H., Hu, S., Li, W., Zuo, Z., & Yifan, H. (2012) · InTech eBooks · doi:10.5772/35663
“The success of memantine in clinical trials led to its being approved by FDA to treat moderate to severe AD in 2003 (Lipton, 2006).”
Herpesvirus Infection and Immunity in Neurocognitive Disorders
Westman, G. (2015) · Uppsala University Publications (Uppsala University)
Der Einfluss des TGF-ß-Signalwegs auf das Überleben retinaler Ganglienzellen
Abramov, N. (2016) · University of Regensburg Publication Server (University of Regensburg)
Preparative-scale synthesis of ZL006 and its derivatives
Zhu, D.-Y., Li, F., Luo, C.-X., Ji, X., & Zhu, D.-Y. (2011) · Protocol Exchange · doi:10.1038/protex.2011.213
Amyloid beta 4-42 in Alzheimer’s disease: Target, Therapy, Mechanism
Antonios, G. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5611 · Cited by 1
Computational Approaches to Ionotropic Glutamate Receptors
Vijayan, R., Iorga, B. I., & Biggin, P. C. (2010) · Royal Society of Chemistry eBooks · doi:10.1039/9781849732154-00203
de Sousa, F. T. R., & Rodrigues, S. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Kinetic determinants of GABA-A receptor function.
Ej, B. (2010) · Europe PMC (PubMed Central)
Expression, Purification, and Crystallization of Full Length Ionotropic Glutamate Receptors
Yelshanskaya, M. V., Saotome, K., Li, M., & Sobolevsky, A. I. (2015) · Neuromethods · doi:10.1007/978-1-4939-2812-5_7
Nakamura, T., Hansen, M., Oldham, S., & Lipton, S. A. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6231-8.10025-x
Self-citationMolecular Neurology of HIV-1 Infection and AIDS
Kaul, M., & Lipton, S. A. (2007) · Elsevier eBooks · doi:10.1016/b978-012369509-3.50036-6 · Cited by 1
Self-citationPET studies in Parkinson’s Disease Dyskinesias and Dementia
Ahmed, I. (2012) · Spiral (Imperial College London) · doi:10.25560/9636
Phenotypic Impact of Genetic Risk Pathways for Alzheimer's Disease
Felsky, D. (2016) · TSpace (University of Toronto)
Mechanisms of NMDA receptor inhibition by memantine and ketamine
Glasgow, N. G. (2016) · D-Scholarship@Pitt (University of Pittsburgh)
Pharmaceutical Industry Performance
Swinney, D. C. (2017) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-50042-3_1
Conditions for the emergence of corticostriatal synaptic plasticity
Valtcheva, S. (2016) · theses.fr (ABES) · doi:10.70675/f70ff8c5z00c9z4400za0f8z8b334428eade
Onggowidjaja, P., & Shahib, M. N. (2015) · Journal Of Medicine & Health · doi:10.28932/jmh.v1i2.505
New treatment options for hyperammonemia
Díaz, G. A. (2015) · doi:10.2217/fmeb2013.14.33
Molecular and Synaptic Alterations in the Striatum of GluN1-Deficient Mice
Chen, Y. (2018) · TSpace (University of Toronto)
N‐Methyl‐D‐Aspartate (NMDA) Receptor Antagonists
Ogata, N., & Dantas, L. M. D. S. (2019) · Wiley eBooks · doi:10.1002/9781119226253.ch12
Beggiora, P. D. S. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2019.tde-10102018-160616
Exposition aux organochlorés et démence dans la population âgée du Canada
Medehouenou, T. C. M. (2013)
Role of the NMDA receptor subunit, NR3A, in glutamatergic synapse development
Henson, M. A. (2010) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/s4z0-fd80
Development of an acute excitotoxic model of Huntington's disease in sheep
O’Connell, A. (2020) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Stargazin Interaction With Serine Racemase Mediates Cerebral Ischemia/Reperfusion Injury in RatsPreprint
Yuan, X., Diao, S., Chen, S., Lu, J., Shen, H., Li, H., Li, X., Wu, J., Liu, C., Yang, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-999457/v1
Beal, M. F. (2009) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1260969.728071
Lipton, S. A., & Nakamura, T. (2009) · Oxidative stress and disease · doi:10.1201/9781420073522.ch6
Self-citationYoung, R. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc242.pub2
Epigenetics in child psychiatry
Elia, J., Izaki, Y., Borreggine, K. L., Yost, O., Castro, A., Chang, C. Y., Ambrosini, A. P., Fels, S., Poddar, K., Rayfield, J., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823577-5.00012-x
Luca, M. D., & Gardoni, F. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717097868.792402829
Nakamura, T., & Lipton, S. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-21573-6_10041-1
Self-citationPharmacological interventions in mild cognitive impairment and dementia
Hugon, J., & Paquet, C. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198701590.003.0128
Polypharmacology in Clinical Applications: Neurological Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_6
Schade, N. J. D. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9562
Wang, X., Li, Z., Zhang, X., Kang, M., Lv, C., Zhang, X., Zhao, Z., Wu, Y., Song, P., & Wang, R. (2023) · Journal of Chemistry · doi:10.1155/2023/8838634
Li, C., Mi, H., Tao, Y., Lei, X., Sun, R., Xiao, L., Le, J., Xu, S. Q., Song, L., & Du, X. (2024) · Research Square · doi:10.21203/rs.3.rs-4020634/v1 · Cited by 1
NEW HYBRID STRUCTURES BASED ON MEMANTHINE AND EDARAVONE MOLECULES
Grigoriev, V. V., Aksinenko, A. Y., Shevtsova, E. F., Горева, Т. В., Veselov, I. M., Gabrel’yan, A. V., & Бачурин, С. О. (2023) · Доклады Российской академии наук Науки о жизни · doi:10.31857/s2686738923600413
A Comprehensive Review on the Newer Therapeutic Approaches in Treating Alzheimer’s Disease
Prakash, R., Jayaraman, R., Palei, N. N., Prakash, D. J., & Ronald, D. (2024) · Springer eBooks · doi:10.1007/978-981-19-3949-5_40-1 · Cited by 1
A Comprehensive Review on the Newer Therapeutic Approaches in Treating Alzheimer’s Disease
Prakash, R., Jayaraman, R., Palei, N. N., Prakash, D. J., & Ronald, D. (2024) · Springer eBooks · doi:10.1007/978-981-99-7557-0_40
Costa, P. W., Bastos, A. M., Bastos, S., & Gattass, R. (2025) · Preprints.org · doi:10.20944/preprints202505.0802.v1
Ghatak, S., & Lipton, S. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_18
Self-citationFerrassi, H., Ouchaoui, A. A., Hakmi, M., Ghammaz, H., Hadad, S. E. E., El-Ghandouri, Y., Kartti, S., Fahime, E. E., Bourais, I., & Elouafy, Y. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111151
Therapeutic approaches to age related cognitive decline and neurodegenerative diseases
Nandi, N. K., Singhal, A., & Tripathi, P. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36295-8.00009-2
Receptor targets in Alzheimer's disease drug discovery
Stanley, B., Wallach, J. V., & Adejare, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00013-2 · Cited by 1
Studies on spreading depolarization in healthy and metabolically compromised brain tissues
Aiba, I. (2012) · UNM’s Digital Repository (University of New Mexico)
Rivas‐Santisteban, R., Lillo, A., Lillo, J., Rebassa, J.-B., Contestí, J. S., Saura, C. A., Franco, R., & Navarro, G. (2021) · Figshare · doi:10.6084/m9.figshare.16960423
Investigating polygenic risk scores in Alzheimer's disease
Chaudhury, S. R. (2024) · Nottingham ePrints (University of Nottingham)
Zenki, K. C. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Leuzy, A. (2015) · eScholarship@McGill (McGill) · doi:10.82308/27371
Zenki, K. C., Kalinine, E., Mussulini, B. H. M., dos Santos, T. G., von Mengden, L., Klamt, F., Baggio, S., de Moura, A. C., da Veiga, A. B. G., & de Oliveira, D. L. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70345
“The anticonvulsant efficacy of memantine, evidenced by increased latency to tonic–clonic seizures and reduced overall seizure intensity, is consistent with its established pharmacology as an uncompetitive NMDAR blocker (Lipton 2006).”
Cota, A. A. B. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
(Schwer‐) Metalle und Gehirn gehen gar nicht? Denkste!
Becker, S. (2026) · Chemie in unserer Zeit · doi:10.1002/ciuz.70021
Tiliwaerde, M., Dong, Z., Jingjing, L., Qi, L., Hongxian, J., Huan, G., Shen, W., Wei, G., & Jin, Z. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70359
“To benchmark GW201 against established NMDA receptor-targeted therapies, we performed direct comparisons with memantine, a clinically approved uncompetitive NMDA receptor antagonist (Lipton, 2006; Parsons et al., 2007”
Zhang, X., Yu, X., Longze, 沙. S., Li, Y., Qiao, Q., 俞晓明, & Xu, Q. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.017
“However, most NMDAR antagonists are competitive, and they tend to interfere with normal brain function, often resulting in significant side effects 60 .”
Çakır, C. Ö., Yumuşak, N., Tekeli, M. Y., Bayram, D., Bayram, L. Ç., & Baloğlu, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1739566
“…of I/R injury is characterized by a complex interplay of glutamate-mediated excitotoxicity, intracellular calcium overload, mitochondrial dysfunction, oxidative stress, neuroinflammation, and activation of apoptotic signaling pathways (Lipton, 2006; Zhang et al., 2023; Rehman et al., 2024).”
Synthèse et évaluation pharmacologique de nouveaux peptides biomimétiques et de benzothiadiazines
Kihal, N. (2013) · theses.fr (ABES) · doi:10.70675/fb113a35z7115z4421zb874z33112254e4a3
Cochet, M. (2011) · theses.fr (ABES) · doi:10.70675/599a8bbez3c0bz407dzbd52z0872ed5f8f6d · Cited by 1
NMDA receptor of the blood brain barrier : mechanism of action and interaction with tPA
Mehra, A. (2017) · theses.fr (ABES) · doi:10.70675/15fd85bbzf823z4447za49az720e0988f6ab
Leão, A. V. M., Bíscaro, G. G., de Oliveira, A. L. R., & Cartarozzi, L. P. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70429
“…increase may reflect either preferential extrasynaptic NMDA blockade at lower doses, allowing VGLUT-1 upregulation, or compensatory VGLUT-1 expression in response to partial NMDA inhibition, both consistent with dose-dependent NMDA effects on synaptic plasticity (Lipton 2006; Wu et al. 2009).”
Exploring the molecular determinants of behavioral changes induced by ketamine at the nanoscale
Uyttersprot, F. (2024) · theses.fr (ABES) · doi:10.70675/df438baaz92d0z488aza38cz4227b46c9acb
Memantine as a pain management strategy post-total knee arthroplasty: a randomized controlled trial
Daneshmand, S., Amiri, S., Soleimani, M., Khonji, M. S., Mehrpooya, M., Moghtadaei, M., & Eshraghi, A. (2026) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-026-04675-4
Esmaili‐Shahzade‐Ali‐Akbari, P., Alani, B., Hosseini, E. S., Banafshe, H. R., Ardjmand, A., Nooshabadi, M. R., Haghparast, A., & Ghaderi, A. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05222-y
“Consequently, its dysregulation has been implicated in the pathophysiology of various neurological disorders (Rodríguez-Muñoz et al. 2012; Maeng and Zarate 2007; Mechri et al. 2001; Lipton 2006).”
In vitro and in vivo inhibition of amyloid β aggregation by a Ru( ii )–naphthalene diimide complex
Tiburcio, M. A., Cali, M. P., Pereira, L. M. B., Graminha, A. E., Atienza‐Navarro, I., Vendruscolo, M., García-Alloza, M., & Carlos, R. M. (2026) · Dalton Transactions · doi:10.1039/d5dt02853a
Ren, K. (2026) · Journal of Medical and Health Studies · doi:10.32996/jmhs.2027.7.7.11
“The NMDAR modulator memantine, for example, may paradoxically upregulate synaptic receptor trafficking in states of hypofunction and has shown promise in pilot studies for SLE-related cognitive dysfunction [39].”
Metadata
- Authors
- Lipton, S. A.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Lipton, Stuart A.
- ORCID
- Lipton, Stuart A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 160-170
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981238903
- Cited by
- 909
- References
- 98
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 32 · 2023: 31 · 2022: 40 · 2021: 41 · 2020: 51 · 2019: 42 · 2018: 36 · 2017: 40 · 2016: 48 · 2015: 51 · 2014: 47 · 2013: 48 · 2012: 52
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- memantine, NMDA receptor antagonists, neuroprotection, Alzheimer's disease, dementia, glutamate excitotoxicity, calcium influx, free radicals, adverse drug reactions, clinical trial failure, NMDA receptor overactivation
- MeSH terms
- Animals, Humans, Memantine, Neurotoxins, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.